Skip to main navigation
Skip to search
Skip to main content
Rutgers, The State University of New Jersey Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Federal Grants
Research output
Search by expertise, name or affiliation
Refractory DLBCL: Challenges and Treatment
Mendel Goldfinger
, Dennis L. Cooper
Cancer Institute of New Jersey (CINJ)
Research output
:
Contribution to journal
›
Review article
›
peer-review
19
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Refractory DLBCL: Challenges and Treatment'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Refractory Diffuse Large B-cell Lymphoma
100%
Treatment Failure
66%
Recurrent Disease
66%
Monoclonal Antibody
33%
Early Treatment
33%
Older Patients
33%
Chimeric Antigen Receptor T Cells (CAR-T)
33%
Clinical Relapse
33%
Treatment Therapy
33%
Novel Agents
33%
Positron Emission Tomography-computed Tomography (PET-CT)
33%
Treatment Monitoring
33%
Initial Treatment
33%
Antibody-drug Conjugate
33%
Early Use
33%
Autologous Transplantation
33%
Disease Control
33%
Bispecific T-cell Engager (BiTE)
33%
Long-term Disease
33%
Cusp
33%
Frontline Treatment
33%
Hodgkin Lymphoma
33%
Pathologic Factors
33%
Circulating Tumor DNA (ctDNA)
33%
Early Recognition
33%
High-dose Therapy
33%
R-CHOP
33%
T Cell Bispecific
33%
Chemotherapy-free
33%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Recurrent Disease
50%
Transplantation
25%
Treatment Response
25%
T Cell
25%
Immunotherapy
25%
Monoclonal Antibody
25%
Drug Megadose
25%
Positron Emission Tomography-Computed Tomography
25%
Hodgkin's Lymphoma
25%
Hope
25%
Chimeric Antigen Receptor T-Cell
25%
Circulating Tumor DNA
25%
Antibody-Drug Conjugate
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Polyethylene Terephthalate
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Recurrent Disease
50%
Polyethylene Terephthalate
50%
Chemotherapy
25%
Immunotherapy
25%
Antibody Drug Conjugate
25%
Monoclonal Antibody
25%
Hodgkin Disease
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Circulating Tumor DNA
25%
Diseases
25%
Neuroscience
B Cell
100%
T Cell
50%
Immunotherapy
25%
Positron Emission Tomography
25%
Positron Emission Tomography-Computed Tomography
25%
Monoclonal Antibody
25%
CHOP
25%
Circulating Tumor DNA
25%
Antibody-Drug Conjugate
25%
Immunology and Microbiology
B Cell
100%
T Cell
25%
Immunotherapy
25%
Monoclonal Antibody
25%
Positron Emission Tomography-Computed Tomography
25%
Antibody Drug Conjugate
25%
Drug Megadose
25%
Chimeric Antigen Receptor T-Cell
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%